UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $562
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Colin Bristow has maintained a Buy rating on Vertex Pharmaceuticals and raised the price target from $477 to $562.
October 17, 2024 | 3:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS analyst Colin Bristow has maintained a Buy rating on Vertex Pharmaceuticals and increased the price target from $477 to $562, indicating a positive outlook for the stock.
The increase in the price target from $477 to $562 by UBS suggests a strong positive outlook for Vertex Pharmaceuticals. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100